Lineage Cell Therapeutics (LCTX) Total Non-Current Liabilities (2016 - 2025)
Lineage Cell Therapeutics' Total Non-Current Liabilities history spans 16 years, with the latest figure at $25.3 million for Q4 2025.
- For Q4 2025, Total Non-Current Liabilities fell 15.69% year-over-year to $25.3 million; the TTM value through Dec 2025 reached $25.3 million, down 15.69%, while the annual FY2025 figure was $25.3 million, 15.69% down from the prior year.
- Total Non-Current Liabilities reached $25.3 million in Q4 2025 per LCTX's latest filing, up from $23.7 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $83.6 million in Q4 2021 to a low of $10.9 million in Q1 2021.
- Average Total Non-Current Liabilities over 5 years is $38.7 million, with a median of $39.0 million recorded in 2023.
- Peak YoY movement for Total Non-Current Liabilities: surged 575.15% in 2021, then tumbled 38.14% in 2022.
- A 5-year view of Total Non-Current Liabilities shows it stood at $83.6 million in 2021, then plummeted by 38.14% to $51.7 million in 2022, then fell by 24.61% to $39.0 million in 2023, then fell by 22.95% to $30.0 million in 2024, then decreased by 15.69% to $25.3 million in 2025.
- Per Business Quant, the three most recent readings for LCTX's Total Non-Current Liabilities are $25.3 million (Q4 2025), $23.7 million (Q3 2025), and $24.9 million (Q2 2025).